Loading
Led the St. Jude medulloblastoma trials that introduced molecular subgroups into risk-adapted treatment.
Amar Gajjar led SJMB96 and SJMB03, the St. Jude medulloblastoma trials that established risk-adapted craniospinal radiotherapy with dose-intensive chemotherapy and showed how WNT, SHH and group 3/4 subgroups predict outcome, and SJMB12, the first trial to assign treatment by molecular subgroup. He co-chairs the Children's Oncology Group CNS committee and directs neuro-oncology at St. Jude.
Shares DNA methylation profiling, Medulloblastoma and the tags paediatric, medulloblastoma.
Shares St. Jude Children's Research Hospital and the tags paediatric, st-jude.
Shares St. Jude Children's Research Hospital, Medulloblastoma and the tag paediatric.
Shares St. Jude Children's Research Hospital and the tag paediatric.
Shares Medulloblastoma, Proton therapy.
Shares St. Jude Children's Research Hospital, DNA methylation profiling, Medulloblastoma, Proton therapy and the tag paediatric.
Shares St. Jude Children's Research Hospital, DNA methylation profiling, Medulloblastoma, Proton therapy and the tag paediatric.
Shares St. Jude Children's Research Hospital, DNA methylation profiling, Medulloblastoma, Proton therapy and the tag paediatric.